We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Strem and Codexis Sign Enzyme Distribution Agreement
News

Strem and Codexis Sign Enzyme Distribution Agreement

Strem and Codexis Sign Enzyme Distribution Agreement
News

Strem and Codexis Sign Enzyme Distribution Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Strem and Codexis Sign Enzyme Distribution Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

These enzymes enable efficient conversion of ketones to chiral alcohols or amines.

The screening kits contain enzymes evolved with proprietary CodeEvolver® directed evolution technology. The resulting enzymes are designed to work at industrial process conditions while reducing cost and waste. They will be available through Strem’s overnight delivery service so that researchers are able to quickly screen a small number of diverse biocatalysts to pick the best solution.

“We are pleased to announce this partnership with Strem, a company very well established in the distribution of catalysts to a wide customer base,” said Dr. Peter Seufer-Wasserthal, Senior Vice President, Pharmaceuticals at Codexis. “Based on Strem’s proven network, we are looking forward to giving more customers the opportunity to use industrial enzymes at R&D scale.”

“Strem is pleased to be working with a proven market leader in the field of Biocatalysis,” said Ephraim Honig, Chief Operating Officer at Strem. “The addition of these screening kits broadens the range of synthesis tools we offer our customers and acknowledges the increasingly important role this technology plays in drug discovery and development.”

Advertisement